Trials / Recruiting
RecruitingNCT03331601
Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients
Evaluation of 68GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Universitair Ziekenhuis Brussel · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the uptake of the radiopharmaceutical 68-GaNOTA-Anti-HER2 VHH1 in brain metastasis using PET/CT imaging. Patients with HER2-positive and HER2-negative cancer will be included and the uptake in their lesions will be compared. Optional 68-GaNOTA-Anti-HER2 VHH1 scans may be performed during or after treatment, at time points 12±6 weeks and 24±9 weeks after the first scan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68GaNOTA-Anti-HER2 VHH1 | Injection of the radiopharmaceutical and PET/CT 90 min post injection |
Timeline
- Start date
- 2017-10-16
- Primary completion
- 2026-09-01
- Completion
- 2026-12-01
- First posted
- 2017-11-06
- Last updated
- 2024-04-24
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03331601. Inclusion in this directory is not an endorsement.